Aytu BioPharma (NASDAQ:AYTU) Stock Rating Lowered by Maxim Group

Aytu BioPharma (NASDAQ:AYTU – Get Free Report) was downgraded by Maxim Group from a “buy” rating to a “hold” rating in a research report issued on Tuesday, Marketbeat.com reports.

A number of other equities analysts also recently issued reports on the company. Zacks Research downgraded Aytu BioPharma from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Citigroup reaffirmed a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday, September 22nd. Weiss Ratings downgraded shares of Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, October 6th. Finally, Lake Street Capital lowered shares of Aytu BioPharma from a “buy” rating to a “hold” rating and set a $2.70 price target for the company. in a research note on Tuesday. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.60.

View Our Latest Stock Analysis on Aytu BioPharma

Aytu BioPharma Price Performance

Aytu BioPharma stock opened at $2.66 on Tuesday. Aytu BioPharma has a fifty-two week low of $1.75 and a fifty-two week high of $3.07. The stock’s 50 day simple moving average is $2.03 and its two-hundred day simple moving average is $2.27. The company has a quick ratio of 1.00, a current ratio of 1.13 and a debt-to-equity ratio of 0.26.

Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.06. The firm had revenue of $14.84 million during the quarter, compared to analyst estimates of $13.27 million. Aytu BioPharma had a negative return on equity of 74.74% and a negative net margin of 34.34%. As a group, equities analysts forecast that Aytu BioPharma will post -0.16 earnings per share for the current year.

Hedge Funds Weigh In On Aytu BioPharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Nantahala Capital Management LLC purchased a new position in shares of Aytu BioPharma in the 2nd quarter worth about $2,336,646. Stonepine Capital Management LLC bought a new position in Aytu BioPharma in the 2nd quarter worth about $1,962,780. AWM Investment Company Inc. purchased a new stake in Aytu BioPharma during the 2nd quarter valued at about $1,332,000. BlackRock Inc. purchased a new stake in Aytu BioPharma during the 2nd quarter valued at about $49,000. Finally, Crown Advisors Management Inc. purchased a new stake in Aytu BioPharma during the 2nd quarter valued at about $430,000. 33.49% of the stock is currently owned by institutional investors.

Top Aytu BioPharma Stories

Investors following AYTU have been watching these stories:

About Aytu BioPharma

(Get Free Report)

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.

Further Reading

Analyst Recommendations for Aytu BioPharma (NASDAQ:AYTU)

Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.